FDA panel backs Astellas drug for invasive fungal infections

FDA panel backs Astellas drug for invasive fungal infections

(Reuters) – A panel of experts on Thursday voted to recommend that U.S. health regulators approve Astellas Pharma Inc's drug for the treatment of rare, often fatal invasive fungal infections that can target patients with blood cancers. The Anti

7
Like
Save

Comments

Write a comment

*